NPS Pharmaceuticals (NPSP) Beats Q2 View By 20c
More News related to NPSP
- NPS Pharmaceuticals Appoints Roger Garceau as Chief Medical Officer
- NPS Pharmaceuticals Initiates Phase 3 'STEPS' Study to Confirm GATTEX(TM) Reduces Parenteral Nutrition Dependence in Short Bowel Syndrome
- NPS Pharmaceuticals to Present at Piper Jaffray Health Care Conference
- Citi Initiates Coverage on NPS Pharmaceuticals (NPSP) with a Buy
- NPS Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference
More News related to Earnings
- Copart (CPRT) Reports Mixed Q3 Results
- Dynamex (DDMX) Misses Street's Q1 Earnings; Guides FY09
- Financial Federal Corp. (FIF) Tops Q1 Earnings Views
- Synopsys (SNPS) Tops Q4 EPS by 5c; Guides
- XETA Technologies (XETA) Reports Flat Q4 EPS of $0.07
NPS Pharmaceuticals (Nasdaq: NPSP) reports a Q2 EPS of $0.03, 20 cents better than the analyst estimate of ($0.17). Revenues for the quarter were $26.96 million, versus the consensus of $22.60 million.
Related Categories
EarningsHot List
Stocks Mentioned
+0.10Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
